

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.2	97.1	(41.8-191.4)	Male	14	5.4	257.1	(140.5-431.5)
Female	3	2.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.6	313.2	(100.9-730.9)	Male	2	1.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	35	34.0	102.9	(71.7-143.2)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	9	9.3	96.9	(44.2-183.9)	<u>Ovary</u>				
Female	4	7.8	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	31	28.5	108.8	(73.9-154.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	6	2.6	230.9	(84.3-502.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.2	130.1	(56.0-256.3)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	8	7.7	104.2	(44.9-205.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	106	111.8	94.8	(77.6-114.6)
Female	1	0.9	nc	(nc-nc)	Female	95	108.0	88.0	(71.2-107.6)
<u>Lung and Bronchus</u>									
Male	14	15.3	91.6	(50.0-153.7)					
Female	9	15.2	59.2	(27.0-112.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.0	85.1	(49.5-136.3)	Male	23	13.0	176.9	(112.1-265.4)
Female	8	8.5	94.6	(40.8-186.5)	Female	18	11.2	160.2	(94.9-253.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	5	3.9	128.8	(41.5-300.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	15	11.6	129.1	(72.2-212.9)
Female	98	93.6	104.7	(85.0-127.6)	Female	10	11.8	85.0	(40.7-156.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	13	10.2	127.3	(67.7-217.7)
<u>Colon / Rectum</u>					Female	5	5.0	100.0	(32.2-233.3)
Male	25	22.2	112.8	(73.0-166.5)	<u>Ovary</u>				
Female	22	24.3	90.6	(56.8-137.2)	Female	6	8.1	74.4	(27.2-161.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	5	7.3	68.1	(22.0-159.0)
Female	0	1.7	nc	(nc-nc)	Female	5	8.6	58.2	(18.8-135.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	91	68.7	132.5	(106.7-162.7)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.9	nc	(nc-nc)
Male	9	11.8	76.3	(34.8-144.8)	Female	3	3.3	nc	(nc-nc)
Female	3	7.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	0	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	11	5.2	211.8	(105.6-379.0)
<u>Leukemia</u>					Female	23	15.7	146.1	(92.6-219.3)
Male	7	8.1	86.2	(34.5-177.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.6	nc	(nc-nc)	Female	25	21.7	115.3	(74.6-170.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.5	nc	(nc-nc)	Male	283	268.7	105.3	(93.4-118.4)
Female	3	2.8	nc	(nc-nc)	Female	309	312.7	98.8	(88.1-110.5)
<u>Lung and Bronchus</u>									
Male	27	36.4	74.2	(48.9-108.0)					
Female	39	44.9	86.9	(61.8-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	95	96.7	98.3	(79.5-120.2)	Male	72	59.7	120.7	(94.4-152.0)
Female	43	34.2	125.6	(90.9-169.1)	Female	67	46.8	143.2	(110.9-181.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	17.9	122.6	(76.8-185.6)	Male	31	19.4	159.8	(108.6-226.9)
Female	17	15.4	110.2	(64.2-176.5)	Female	16	15.6	102.7	(58.7-166.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.3	nc	(nc-nc)	Male	66	53.9	122.4	(94.6-155.7)
Female	434	377.4	115.0	(104.4-126.4)	Female	61	47.9	127.3	(97.4-163.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	12.5	64.0	(27.5-126.0)	Male	26	43.5	59.7	(39.0-87.5)
<u>Colon / Rectum</u>					Female	32	20.3	157.9	(108.0-223.0)
Male	88	101.9	86.4	(69.3-106.4)	<u>Ovary</u>				
Female	76	100.7	75.4	(59.4-94.4)	Female	46	32.6	141.1	(103.3-188.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	24.3	49.3	(25.5-86.2)	Male	34	33.9	100.2	(69.4-140.1)
Female	7	6.7	105.0	(42.1-216.4)	Female	49	35.1	139.6	(103.3-184.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	6.9	101.9	(40.8-210.0)	Male	326	294.3	110.8	(99.1-123.5)
Female	3	6.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	22.9	91.6	(56.7-140.0)
Male	51	51.6	98.9	(73.6-130.0)	Female	14	13.7	102.1	(55.8-171.3)
Female	19	30.0	63.3	(38.1-98.9)	<u>Testis</u>				
<u>Larynx</u>					Male	12	11.6	103.2	(53.3-180.3)
Male	10	14.1	71.1	(34.0-130.7)	<u>Thyroid</u>				
Female	1	4.2	nc	(nc-nc)	Male	34	22.6	150.4	(104.1-210.1)
<u>Leukemia</u>					Female	87	69.0	126.0	(100.9-155.5)
Male	37	38.5	96.1	(67.7-132.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	28.1	88.9	(57.5-131.2)	Female	91	84.5	107.7	(86.7-132.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	32.3	77.5	(50.1-114.4)	Male	1166	1218.8	95.7	(90.3-101.3)
Female	9	11.2	80.0	(36.5-151.9)	Female	1376	1274.1	108.0	(102.4-113.9)
<u>Lung and Bronchus</u>									
Male	124	170.1	72.9	(60.6-86.9)					
Female	157	177.5	88.5	(75.2-103.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.4	70.4	(30.3-138.8)	Male	20	8.6	233.1	(142.3-360.0)
Female	1	2.5	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.8	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.6	65.8	(21.2-153.5)
Female	42	37.2	112.9	(81.4-152.7)	Female	1	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	7.3	68.2	(22.0-159.1)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	12	14.0	85.6	(44.2-149.5)	<u>Ovary</u>				
Female	7	7.8	90.3	(36.2-186.0)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	170.5	(62.3-371.1)	Male	2	4.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	40	45.7	87.4	(62.5-119.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	11	8.3	133.3	(66.5-238.5)	Female	1	1.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.2	110.5	(47.6-217.8)
Male	4	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	5	8.6	58.2	(18.7-135.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.2	nc	(nc-nc)	Male	154	174.6	88.2	(74.8-103.3)
Female	1	1.0	nc	(nc-nc)	Female	103	113.7	90.6	(74.0-109.9)
<u>Lung and Bronchus</u>									
Male	18	21.7	83.0	(49.2-131.2)					
Female	12	14.2	84.6	(43.7-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.2	98.6	(57.4-157.9)	Male	5	10.4	47.9	(15.4-111.7)
Female	11	6.1	179.7	(89.6-321.6)	Female	7	7.8	89.9	(36.0-185.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.3	85.7	(36.9-168.9)
Female	52	63.1	82.5	(61.6-108.1)	Female	7	8.3	84.6	(33.9-174.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	9	7.2	124.6	(56.8-236.5)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	26	17.6	147.8	(96.5-216.6)	<u>Ovary</u>				
Female	16	17.5	91.5	(52.3-148.6)	Female	5	5.5	91.2	(29.4-212.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	192.8	(83.0-379.9)	Male	0	5.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	10	6.3	159.8	(76.5-293.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	43	47.7	90.2	(65.2-121.4)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.0	nc	(nc-nc)
Male	13	8.7	149.9	(79.7-256.3)	Female	2	2.4	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.7	nc	(nc-nc)	Male	5	3.8	131.6	(42.4-307.2)
<u>Leukemia</u>					Female	7	10.8	64.6	(25.9-133.0)
Male	5	6.7	74.7	(24.1-174.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.8	nc	(nc-nc)	Female	12	14.0	85.9	(44.3-150.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	5.4	166.9	(76.2-316.8)	Male	206	208.5	98.8	(85.7-113.2)
Female	3	1.9	nc	(nc-nc)	Female	209	217.0	96.3	(83.7-110.3)
<u>Lung and Bronchus</u>									
Male	27	30.2	89.4	(58.9-130.0)					
Female	46	31.8	144.6	(105.9-192.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	29.3	143.5	(103.4-194.0)	Male	15	19.0	79.0	(44.2-130.3)
Female	9	11.5	78.3	(35.7-148.7)	Female	16	15.6	102.7	(58.7-166.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.9	101.2	(37.0-220.3)	Male	6	6.0	99.5	(36.3-216.6)
Female	6	5.0	119.9	(43.8-261.0)	Female	6	5.2	115.4	(42.1-251.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	19	17.1	111.0	(66.8-173.4)
Female	115	126.4	91.0	(75.1-109.2)	Female	15	15.9	94.1	(52.7-155.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.2	nc	(nc-nc)	Male	9	14.4	62.4	(28.5-118.5)
<u>Colon / Rectum</u>					Female	3	6.7	nc	(nc-nc)
Male	28	32.6	85.8	(57.0-124.1)	<u>Ovary</u>				
Female	43	34.3	125.3	(90.7-168.8)	Female	8	10.8	74.0	(31.8-145.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.6	79.2	(28.9-172.4)	Male	10	10.5	94.9	(45.4-174.6)
Female	1	2.2	nc	(nc-nc)	Female	9	11.8	76.2	(34.8-144.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	93	91.4	101.7	(82.1-124.6)
Female	4	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.1	98.1	(39.3-202.1)
Male	15	16.7	89.8	(50.2-148.1)	Female	7	4.7	150.1	(60.1-309.3)
Female	5	10.0	50.0	(16.1-116.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.2	nc	(nc-nc)
Male	0	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	13	7.8	165.8	(88.2-283.6)
<u>Leukemia</u>					Female	21	23.0	91.3	(56.5-139.6)
Male	12	12.2	98.0	(50.6-171.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.3	117.9	(58.8-211.0)	Female	22	27.5	80.1	(50.2-121.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.5	57.3	(20.9-124.8)	Male	372	382.9	97.2	(87.5-107.6)
Female	5	3.7	135.2	(43.6-315.5)	Female	388	425.4	91.2	(82.4-100.8)
<u>Lung and Bronchus</u>									
Male	37	51.2	72.2	(50.8-99.5)					
Female	47	59.1	79.5	(58.4-105.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.5	93.5	(57.8-142.9)	Male	14	16.0	87.4	(47.7-146.6)
Female	7	8.5	82.1	(32.9-169.3)	Female	22	13.4	164.1	(102.8-248.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.4	92.1	(29.7-214.9)	Male	6	5.0	119.1	(43.5-259.2)
Female	7	4.4	158.9	(63.7-327.5)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	17	14.4	117.6	(68.5-188.4)
Female	107	108.0	99.1	(81.2-119.7)	Female	14	12.7	110.2	(60.2-184.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	11	13.0	84.5	(42.1-151.3)
<u>Colon / Rectum</u>					Female	6	5.5	109.6	(40.0-238.6)
Male	34	26.9	126.3	(87.5-176.5)	<u>Ovary</u>				
Female	23	26.5	86.9	(55.1-130.4)	Female	4	9.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.4	125.0	(53.8-246.3)	Male	10	8.6	116.1	(55.6-213.5)
Female	1	1.7	nc	(nc-nc)	Female	9	8.8	102.7	(46.9-195.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	84	81.8	102.7	(81.9-127.2)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.8	nc	(nc-nc)
Male	15	14.9	100.3	(56.1-165.5)	Female	4	3.6	nc	(nc-nc)
Female	10	8.2	121.6	(58.2-223.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	6	3.8	157.4	(57.5-342.5)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	7.5	93.3	(37.4-192.2)
<u>Leukemia</u>					Female	22	22.1	99.5	(62.3-150.6)
Male	6	10.2	58.6	(21.4-127.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.6	79.0	(28.9-172.0)	Female	19	23.5	80.7	(48.6-126.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.2	87.1	(37.5-171.7)	Male	333	325.4	102.3	(91.6-113.9)
Female	1	2.9	nc	(nc-nc)	Female	337	349.5	96.4	(86.4-107.3)
<u>Lung and Bronchus</u>									
Male	40	41.6	96.3	(68.8-131.1)					
Female	41	45.0	91.2	(65.4-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	13	19.5	66.7	(35.5-114.0)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	7	5.1	136.4	(54.6-281.0)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	15.1	119.1	(70.6-188.3)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	8	4.2	190.0	(81.8-374.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	68	62.5	108.7	(84.4-137.8)
Female	2	0.6	nc	(nc-nc)	Female	63	65.0	96.9	(74.4-123.9)
<u>Lung and Bronchus</u>									
Male	9	8.6	105.0	(47.9-199.4)					
Female	7	9.1	77.3	(31.0-159.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.2	91.3	(48.6-156.1)	Male	15	9.9	152.2	(85.1-251.1)
Female	9	5.4	166.0	(75.7-315.1)	Female	12	8.3	145.4	(75.0-254.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.2	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.8	101.8	(46.5-193.3)
Female	83	69.2	119.9	(95.5-148.6)	Female	5	8.0	62.5	(20.1-145.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	5	8.0	62.7	(20.2-146.3)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	17	16.6	102.4	(59.6-164.0)	<u>Ovary</u>				
Female	13	16.5	78.9	(42.0-135.0)	Female	4	5.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.1	172.8	(69.2-356.1)	Male	4	5.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	6	5.5	108.7	(39.7-236.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	51	51.9	98.2	(73.1-129.1)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	10	9.2	108.9	(52.2-200.4)	Female	0	2.2	nc	(nc-nc)
Female	2	5.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	17	13.1	130.0	(75.7-208.2)
Male	9	6.1	146.6	(66.9-278.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.5	155.9	(62.4-321.1)	Female	17	15.3	111.0	(64.6-177.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.5	(28.2-204.3)	Male	201	202.4	99.3	(86.1-114.1)
Female	3	1.8	nc	(nc-nc)	Female	221	221.1	100.0	(87.2-114.1)
<u>Lung and Bronchus</u>									
Male	19	26.4	71.9	(43.3-112.3)					
Female	25	29.8	83.8	(54.2-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	29.0	106.9	(72.6-151.7)	Male	12	18.5	64.9	(33.5-113.3)
Female	11	11.2	98.5	(49.1-176.3)	Female	10	15.9	62.7	(30.0-115.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	126.0	(50.5-259.7)	Male	1	6.0	nc	(nc-nc)
Female	5	5.2	97.0	(31.3-226.5)	Female	10	5.1	194.6	(93.1-357.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	16	16.7	96.0	(54.8-155.9)
Female	166	124.5	133.3	(113.8-155.2)	Female	13	15.9	81.9	(43.6-140.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.2	nc	(nc-nc)	Male	13	13.8	94.1	(50.1-161.0)
<u>Colon / Rectum</u>					Female	6	6.8	88.8	(32.4-193.2)
Male	30	31.2	96.2	(64.9-137.4)	<u>Ovary</u>				
Female	33	32.7	101.0	(69.5-141.8)	Female	15	11.0	136.6	(76.4-225.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.6	92.1	(36.9-189.7)	Male	8	10.3	77.4	(33.3-152.5)
Female	4	2.2	nc	(nc-nc)	Female	14	11.4	122.8	(67.1-206.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	62	93.6	66.2	(50.8-84.9)
Female	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.0	85.8	(31.3-186.8)
Male	8	16.3	49.0	(21.1-96.6)	Female	4	4.4	nc	(nc-nc)
Female	7	9.9	70.8	(28.4-145.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.1	147.4	(53.8-320.9)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.4	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	24.1	37.3	(17.0-70.8)
Male	11	11.6	94.6	(47.1-169.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.2	75.9	(30.4-156.4)	Female	36	28.7	125.6	(87.9-173.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.1	49.7	(16.0-116.0)	Male	294	378.0	77.8	(69.1-87.2)
Female	3	3.8	nc	(nc-nc)	Female	440	422.2	104.2	(94.7-114.4)
<u>Lung and Bronchus</u>									
Male	39	51.7	75.4	(53.6-103.1)					
Female	46	58.3	79.0	(57.8-105.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.0	131.5	(81.4-201.0)	Male	9	10.3	87.4	(39.9-166.0)
Female	8	5.5	146.1	(62.9-288.0)	Female	6	7.7	78.0	(28.5-169.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	5	2.5	199.0	(64.1-464.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.3	97.0	(44.2-184.1)
Female	80	62.4	128.1	(101.6-159.5)	Female	6	7.8	77.2	(28.2-168.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	5	7.8	63.9	(20.6-149.1)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	10	17.9	56.0	(26.8-103.0)	<u>Ovary</u>				
Female	15	16.6	90.6	(50.7-149.4)	Female	2	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.1	219.1	(100.0-415.9)	Male	6	5.8	103.9	(37.9-226.2)
Female	0	1.1	nc	(nc-nc)	Female	6	5.6	107.5	(39.2-233.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	48	49.7	96.5	(71.2-128.0)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.9	nc	(nc-nc)
Male	7	9.0	77.6	(31.1-159.8)	Female	2	2.2	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	9	11.5	78.5	(35.8-148.9)
Male	9	6.5	138.5	(63.2-262.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.5	109.9	(35.4-256.6)	Female	15	13.7	109.1	(61.0-180.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.7	nc	(nc-nc)	Male	179	207.7	86.2	(74.0-99.8)
Female	1	1.8	nc	(nc-nc)	Female	206	208.0	99.0	(86.0-113.5)
<u>Lung and Bronchus</u>									
Male	13	28.1	46.3	(24.6-79.1)					
Female	24	28.5	84.1	(53.9-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.6	108.7	(63.3-174.0)	Male	11	10.3	107.0	(53.4-191.5)
Female	6	5.6	106.4	(38.9-231.7)	Female	10	8.2	121.6	(58.2-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.2	nc	(nc-nc)	Male	10	3.3	301.4	(144.3-554.3)
Female	1	2.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	9.2	65.1	(23.8-141.7)
Female	53	65.3	81.2	(60.8-106.2)	Female	9	8.1	111.1	(50.7-210.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	10	7.8	128.6	(61.6-236.5)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	10	17.4	57.4	(27.5-105.6)	<u>Ovary</u>				
Female	24	16.9	141.9	(90.9-211.1)	Female	5	5.6	89.4	(28.8-208.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.1	nc	(nc-nc)	Male	5	5.7	87.9	(28.3-205.1)
Female	1	1.1	nc	(nc-nc)	Female	7	5.8	121.3	(48.6-249.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	54	50.1	107.8	(80.9-140.6)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.9	nc	(nc-nc)
Male	14	9.1	154.2	(84.2-258.7)	Female	2	2.3	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.8	85.7	(42.7-153.4)
Male	3	6.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.9	nc	(nc-nc)	Female	21	14.4	146.0	(90.3-223.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	197	207.3	95.1	(82.2-109.3)
Female	1	1.9	nc	(nc-nc)	Female	213	217.8	97.8	(85.1-111.9)
<u>Lung and Bronchus</u>									
Male	28	28.2	99.4	(66.0-143.7)					
Female	25	29.3	85.4	(55.2-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	11	13.9	79.4	(39.6-142.0)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	4.1	121.7	(39.2-283.9)	<u>Ovary</u>				
Female	2	3.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	13.1	53.3	(21.3-109.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.9	nc	(nc-nc)	Female	5	3.2	156.2	(50.3-364.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	35	50.0	70.0	(48.7-97.3)
Female	0	0.4	nc	(nc-nc)	Female	39	45.0	86.6	(61.6-118.4)
<u>Lung and Bronchus</u>									
Male	3	6.6	nc	(nc-nc)					
Female	5	6.2	81.0	(26.1-189.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.5	74.3	(39.5-127.0)	Male	14	11.8	119.0	(65.0-199.7)
Female	7	6.2	113.7	(45.6-234.3)	Female	11	9.3	117.8	(58.7-210.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	132.8	(42.8-310.0)	Male	2	3.7	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	10.6	66.0	(26.5-136.0)
Female	75	75.2	99.8	(78.5-125.1)	Female	10	9.0	110.5	(52.9-203.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	8	9.4	85.3	(36.7-168.2)
<u>Colon / Rectum</u>					Female	3	3.9	nc	(nc-nc)
Male	26	20.0	129.7	(84.7-190.0)	<u>Ovary</u>				
Female	20	19.0	105.2	(64.3-162.5)	Female	7	6.5	108.0	(43.3-222.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.8	125.2	(45.7-272.6)	Male	9	6.5	139.4	(63.6-264.7)
Female	1	1.2	nc	(nc-nc)	Female	11	6.4	172.9	(86.2-309.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	51	59.9	85.1	(63.4-111.9)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	14	10.7	130.5	(71.3-218.9)	Female	2	2.6	nc	(nc-nc)
Female	8	5.8	138.9	(59.8-273.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	8	5.1	155.8	(67.1-307.0)
<u>Leukemia</u>					Female	15	14.8	101.6	(56.8-167.6)
Male	8	7.5	106.7	(45.9-210.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.3	151.9	(65.4-299.4)	Female	22	16.8	131.1	(82.1-198.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.7	104.3	(41.8-214.9)	Male	237	240.8	98.4	(86.3-111.8)
Female	1	2.1	nc	(nc-nc)	Female	256	246.3	103.9	(91.6-117.5)
<u>Lung and Bronchus</u>									
Male	27	31.6	85.3	(56.2-124.2)					
Female	26	32.3	80.6	(52.6-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.5	96.1	(49.6-167.9)	Male	8	7.8	102.5	(44.2-202.1)
Female	4	4.6	nc	(nc-nc)	Female	13	6.0	218.2	(116.1-373.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.4	254.4	(92.9-553.7)	Male	1	2.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	5	2.1	239.2	(77.1-558.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.0	99.7	(39.9-205.4)
Female	48	50.1	95.8	(70.7-127.1)	Female	11	6.4	173.1	(86.3-309.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.9	85.2	(27.5-198.9)
<u>Colon / Rectum</u>					Female	5	2.7	187.6	(60.4-437.7)
Male	10	13.5	73.8	(35.3-135.7)	<u>Ovary</u>				
Female	8	13.5	59.1	(25.4-116.4)	Female	6	4.3	139.9	(51.1-304.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	39	38.3	101.8	(72.4-139.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.0	nc	(nc-nc)
Male	6	6.8	88.0	(32.1-191.6)	Female	1	1.8	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.2	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.6	nc	(nc-nc)	Female	16	11.1	144.5	(82.6-234.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.3	163.0	(65.3-335.9)	Male	147	159.0	92.5	(78.1-108.7)
Female	0	1.5	nc	(nc-nc)	Female	161	168.0	95.8	(81.6-111.8)
<u>Lung and Bronchus</u>									
Male	13	21.9	59.4	(31.6-101.5)					
Female	13	24.2	53.8	(28.6-92.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	32.1	49.9	(28.5-81.0)	Male	34	20.0	169.7	(117.5-237.1)
Female	10	12.7	78.8	(37.7-144.9)	Female	25	16.5	151.5	(98.0-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.0	166.1	(79.5-305.5)	Male	7	6.4	109.0	(43.7-224.6)
Female	6	5.3	114.3	(41.7-248.7)	Female	7	5.7	123.4	(49.4-254.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	17.9	100.7	(59.7-159.2)
Female	137	131.0	104.6	(87.8-123.6)	Female	20	17.3	115.5	(70.5-178.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.3	nc	(nc-nc)	Male	17	14.2	120.0	(69.9-192.2)
<u>Colon / Rectum</u>					Female	6	7.1	84.1	(30.7-183.1)
Male	52	33.9	153.4	(114.6-201.2)	<u>Ovary</u>				
Female	56	37.2	150.7	(113.8-195.7)	Female	12	11.4	105.3	(54.3-183.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.9	126.6	(60.6-232.8)	Male	17	11.1	153.2	(89.2-245.3)
Female	3	2.4	nc	(nc-nc)	Female	19	12.9	146.8	(88.3-229.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	79	90.5	87.3	(69.1-108.8)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	7.6	131.2	(62.8-241.4)
Male	14	16.9	82.9	(45.3-139.1)	Female	5	5.1	98.8	(31.8-230.5)
Female	16	10.6	150.9	(86.2-245.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.4	158.0	(63.3-325.5)
Male	7	4.6	153.7	(61.6-316.7)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	13	7.8	167.6	(89.1-286.6)
<u>Leukemia</u>					Female	27	23.4	115.5	(76.1-168.0)
Male	11	12.9	85.5	(42.6-153.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	10.1	118.7	(61.3-207.3)	Female	30	28.4	105.6	(71.2-150.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	10.5	124.2	(66.1-212.4)	Male	449	397.7	112.9	(102.7-123.9)
Female	2	4.0	nc	(nc-nc)	Female	522	452.3	115.4	(105.7-125.8)
<u>Lung and Bronchus</u>									
Male	58	56.1	103.4	(78.5-133.7)					
Female	87	65.3	133.3	(106.8-164.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.6	118.2	(53.9-224.4)	Male	8	4.5	176.6	(76.0-348.0)
Female	0	2.4	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	24.0	100.1	(64.1-148.9)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.3	nc	(nc-nc)
Male	9	7.5	120.0	(54.8-227.8)	<u>Ovary</u>				
Female	4	6.8	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.8	nc	(nc-nc)	Male	5	2.6	189.0	(60.9-441.0)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	21.1	75.7	(43.2-122.9)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.7	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	7	5.5	128.0	(51.3-263.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	84	90.7	92.6	(73.9-114.6)
Female	0	0.8	nc	(nc-nc)	Female	81	83.2	97.3	(77.3-121.0)
<u>Lung and Bronchus</u>									
Male	11	13.8	80.0	(39.9-143.1)					
Female	15	12.5	119.9	(67.1-197.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	7.5	93.8	(37.6-193.2)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.4	107.5	(46.3-211.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	23	29.1	78.9	(50.0-118.5)
Female	0	0.2	nc	(nc-nc)	Female	22	23.4	94.0	(58.9-142.3)
<u>Lung and Bronchus</u>									
Male	4	3.9	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.4	85.4	(36.8-168.2)	Male	1	6.0	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.2	(40.6-242.1)
Female	33	35.2	93.7	(64.5-131.6)	Female	4	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	5	10.0	49.8	(16.1-116.3)	<u>Ovary</u>				
Female	6	8.7	69.1	(25.2-150.4)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	28	30.6	91.5	(60.8-132.2)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	7	5.3	131.9	(52.8-271.8)	Female	0	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.2	80.7	(26.0-188.3)
Male	4	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	12	8.1	147.7	(76.2-258.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.4	nc	(nc-nc)	Male	111	123.1	90.2	(74.2-108.6)
Female	1	1.0	nc	(nc-nc)	Female	118	115.3	102.3	(84.7-122.5)
<u>Lung and Bronchus</u>									
Male	20	17.2	116.4	(71.1-179.7)					
Female	19	16.3	116.7	(70.3-182.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	15.4	84.2	(44.8-144.1)	Male	21	8.4	249.4	(154.3-381.3)
Female	5	5.1	98.9	(31.9-230.7)	Female	12	5.3	224.3	(115.8-391.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	7.5	172.8	(91.9-295.5)
Female	61	46.2	132.1	(101.0-169.7)	Female	6	6.4	93.4	(34.1-203.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	14	14.2	98.8	(54.0-165.7)	<u>Ovary</u>				
Female	13	13.4	97.0	(51.6-165.8)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.7	nc	(nc-nc)	Male	5	5.1	98.3	(31.7-229.3)
Female	0	1.0	nc	(nc-nc)	Female	8	5.1	157.7	(67.9-310.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	43.8	73.1	(50.0-103.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	2	6.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	10	5.2	190.6	(91.2-350.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.5	nc	(nc-nc)	Female	8	10.9	73.6	(31.7-145.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	153	176.3	86.8	(73.6-101.7)
Female	0	1.6	nc	(nc-nc)	Female	175	163.2	107.2	(91.9-124.3)
<u>Lung and Bronchus</u>									
Male	8	27.6	29.0	(12.5-57.2)					
Female	18	26.7	67.3	(39.9-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	14	7.6	185.0	(101.1-310.4)	Female	3	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	8.5	82.7	(33.1-170.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	24	33.8	71.1	(45.5-105.8)
Female	0	0.2	nc	(nc-nc)	Female	32	25.1	127.7	(87.3-180.3)
<u>Lung and Bronchus</u>									
Male	7	4.9	141.4	(56.7-291.4)					
Female	6	3.8	156.5	(57.2-340.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.9	137.6	(77.0-227.0)	Male	12	7.9	151.2	(78.0-264.1)
Female	6	4.9	123.1	(44.9-267.9)	Female	12	7.2	167.4	(86.4-292.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	6	2.5	241.0	(88.0-524.7)
Female	0	2.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.1	155.0	(77.3-277.4)
Female	58	58.3	99.6	(75.6-128.7)	Female	11	7.1	155.2	(77.4-277.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	8	6.5	122.5	(52.8-241.4)
<u>Colon / Rectum</u>					Female	4	3.0	nc	(nc-nc)
Male	11	13.3	82.8	(41.3-148.2)	<u>Ovary</u>				
Female	15	14.5	103.2	(57.7-170.2)	Female	8	5.0	160.7	(69.2-316.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	6	4.9	123.1	(44.9-267.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	41.2	97.1	(69.3-132.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	6	7.5	79.6	(29.1-173.2)	Female	3	1.9	nc	(nc-nc)
Female	6	4.6	131.8	(48.1-286.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	7	3.8	185.5	(74.3-382.2)
<u>Leukemia</u>					Female	15	11.1	135.2	(75.6-223.0)
Male	10	5.0	198.4	(95.0-364.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.1	172.7	(69.2-355.9)	Female	20	13.1	152.6	(93.2-235.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	4.6	197.3	(90.0-374.5)	Male	202	161.3	125.2	(108.5-143.7)
Female	1	1.7	nc	(nc-nc)	Female	223	191.3	116.6	(101.8-132.9)
<u>Lung and Bronchus</u>									
Male	41	20.5	200.2	(143.6-271.5)					
Female	26	26.1	99.5	(65.0-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	11.1	179.7	(109.7-277.5)	Male	13	7.8	165.6	(88.1-283.3)
Female	8	4.9	163.7	(70.5-322.5)	Female	7	6.7	104.6	(41.9-215.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.5	279.4	(111.9-575.8)	Male	1	2.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	61	54.1	112.7	(86.2-144.8)	Female	8	6.8	117.6	(50.6-231.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.3	94.8	(34.6-206.3)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	13	13.1	99.5	(52.9-170.1)	<u>Ovary</u>				
Female	13	14.2	91.6	(48.7-156.7)	Female	8	4.7	171.0	(73.6-337.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	6	5.0	119.2	(43.5-259.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	35	39.8	88.0	(61.3-122.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.9	174.8	(56.3-407.8)
Male	15	7.2	209.5	(117.2-345.6)	Female	4	1.9	nc	(nc-nc)
Female	5	4.3	116.9	(37.7-272.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	5	1.9	261.7	(84.3-610.7)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.8	81.3	(35.0-160.1)
Male	6	4.8	124.5	(45.5-271.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	127.1	(41.0-296.6)	Female	13	12.2	106.2	(56.5-181.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.6	nc	(nc-nc)	Male	184	158.6	116.0	(99.9-134.0)
Female	2	1.6	nc	(nc-nc)	Female	182	182.0	100.0	(86.0-115.6)
<u>Lung and Bronchus</u>									
Male	31	20.9	148.2	(100.7-210.4)					
Female	15	25.5	58.8	(32.9-96.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	97.7	(31.5-227.9)	Male	7	3.3	211.8	(84.8-436.3)
Female	2	1.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	19	20.2	94.0	(56.6-146.8)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	0	5.5	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.1	118.0	(43.1-256.8)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	17.6	124.8	(78.2-189.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.6	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	5	4.8	105.2	(33.9-245.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	74	68.9	107.3	(84.3-134.7)
Female	1	0.6	nc	(nc-nc)	Female	56	67.2	83.3	(62.9-108.2)
<u>Lung and Bronchus</u>									
Male	5	9.4	52.9	(17.1-123.6)					
Female	5	9.4	52.9	(17.1-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	95	74.7	127.2	(102.9-155.5)	Male	40	43.8	91.2	(65.2-124.3)
Female	39	27.7	140.7	(100.0-192.3)	Female	37	33.5	110.5	(77.8-152.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	12.2	65.6	(28.2-129.2)	Male	18	14.3	125.5	(74.3-198.3)
Female	12	10.5	114.8	(59.3-200.6)	Female	17	12.1	140.1	(81.6-224.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.4	nc	(nc-nc)	Male	39	39.3	99.1	(70.5-135.5)
Female	288	265.3	108.6	(96.4-121.8)	Female	63	36.7	171.8	(132.0-219.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.2	146.3	(75.5-255.7)	Male	33	30.3	108.8	(74.9-152.8)
<u>Colon / Rectum</u>					Female	14	15.0	93.2	(50.9-156.3)
Male	62	75.6	82.1	(62.9-105.2)	<u>Ovary</u>				
Female	85	80.6	105.5	(84.3-130.5)	Female	19	23.4	81.3	(48.9-126.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	17.8	90.0	(51.4-146.1)	Male	23	25.3	91.0	(57.7-136.6)
Female	3	5.3	nc	(nc-nc)	Female	23	28.6	80.3	(50.9-120.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.3	nc	(nc-nc)	Male	215	204.5	105.1	(91.5-120.1)
Female	7	3.7	191.6	(76.7-394.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	17.2	81.4	(44.4-136.5)
Male	29	36.2	80.0	(53.6-114.9)	Female	6	11.1	54.1	(19.7-117.7)
Female	12	21.8	55.0	(28.4-96.0)	<u>Testis</u>				
<u>Larynx</u>					Male	9	7.1	125.9	(57.5-239.1)
Male	17	10.1	168.6	(98.1-269.9)	<u>Thyroid</u>				
Female	2	3.1	nc	(nc-nc)	Male	16	15.1	106.1	(60.6-172.2)
<u>Leukemia</u>					Female	44	43.6	100.9	(73.3-135.4)
Male	27	28.2	95.8	(63.1-139.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	21.2	127.5	(84.0-185.5)	Female	53	58.1	91.2	(68.3-119.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	22.9	78.4	(46.5-124.0)	Male	908	884.8	102.6	(96.1-109.5)
Female	13	8.5	152.9	(81.3-261.5)	Female	1032	938.5	110.0	(103.3-116.9)
<u>Lung and Bronchus</u>									
Male	128	127.8	100.2	(83.6-119.1)					
Female	159	137.8	115.4	(98.1-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.7	78.3	(28.6-170.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	25.4	67.0	(39.0-107.3)
Female	1	0.2	nc	(nc-nc)	Female	15	25.6	58.7	(32.8-96.8)
<u>Lung and Bronchus</u>									
Male	2	3.5	nc	(nc-nc)					
Female	1	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.3	116.6	(70.1-182.0)	Male	7	11.1	63.2	(25.3-130.2)
Female	7	5.8	121.3	(48.6-250.0)	Female	15	9.1	164.5	(92.0-271.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	9.9	131.2	(69.8-224.4)
Female	78	75.7	103.0	(81.4-128.6)	Female	8	8.8	91.4	(39.4-180.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	12	8.8	135.8	(70.1-237.3)
<u>Colon / Rectum</u>					Female	4	3.8	nc	(nc-nc)
Male	28	18.6	150.2	(99.8-217.1)	<u>Ovary</u>				
Female	19	17.6	107.9	(64.9-168.5)	Female	6	6.4	94.3	(34.4-205.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.5	110.0	(35.5-256.8)	Male	7	6.1	115.6	(46.3-238.1)
Female	1	1.2	nc	(nc-nc)	Female	5	5.9	85.4	(27.5-199.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	69	58.1	118.8	(92.4-150.4)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.1	146.8	(53.6-319.6)
Male	11	10.2	107.8	(53.8-192.9)	Female	1	2.4	nc	(nc-nc)
Female	7	5.7	122.8	(49.2-253.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	7	4.8	144.4	(57.9-297.6)
<u>Leukemia</u>					Female	24	14.8	161.7	(103.6-240.7)
Male	10	7.0	143.2	(68.6-263.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.0	99.8	(32.1-232.8)	Female	17	17.1	99.4	(57.9-159.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	262	227.5	115.2	(101.7-130.0)
Female	1	2.1	nc	(nc-nc)	Female	269	241.0	111.6	(98.7-125.8)
<u>Lung and Bronchus</u>									
Male	34	29.9	113.6	(78.6-158.7)					
Female	46	31.3	146.8	(107.5-195.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	11.0	45.4	(14.6-106.0)	Male	6	7.6	79.3	(29.0-172.6)
Female	3	3.4	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.7	(23.7-172.0)
Female	52	47.2	110.1	(82.2-144.4)	Female	4	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	6	6.3	95.9	(35.0-208.8)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	14	13.0	107.6	(58.8-180.6)	<u>Ovary</u>				
Female	15	10.5	142.8	(79.9-235.5)	Female	4	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	6	4.2	144.3	(52.7-314.0)
Female	0	0.7	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	30	39.7	75.6	(51.0-107.9)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.8	nc	(nc-nc)
Male	6	7.0	85.1	(31.1-185.3)	Female	0	1.4	nc	(nc-nc)
Female	5	3.5	141.3	(45.6-329.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.3	150.6	(48.5-351.5)
<u>Leukemia</u>					Female	8	9.4	85.3	(36.7-168.2)
Male	5	4.7	105.3	(33.9-245.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.0	nc	(nc-nc)	Female	18	10.6	169.9	(100.6-268.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.5	nc	(nc-nc)	Male	143	155.7	91.8	(77.4-108.2)
Female	0	1.2	nc	(nc-nc)	Female	154	147.7	104.3	(88.4-122.1)
<u>Lung and Bronchus</u>									
Male	26	20.2	128.7	(84.1-188.6)					
Female	17	19.2	88.6	(51.6-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	13.1	76.2	(36.5-140.1)
Female	0	0.1	nc	(nc-nc)	Female	4	11.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.3	112.3	(41.0-244.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	21	22.5	93.5	(57.9-142.9)
Female	1	0.2	nc	(nc-nc)	Female	11	22.4	49.0	(24.4-87.7)
<u>Lung and Bronchus</u>									
Male	3	3.1	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	6	6.8	88.1	(32.2-191.8)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	5.7	158.5	(72.3-300.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	23	21.3	107.7	(68.3-161.7)
Female	0	0.2	nc	(nc-nc)	Female	21	20.7	101.5	(62.8-155.2)
<u>Lung and Bronchus</u>									
Male	4	2.6	nc	(nc-nc)					
Female	5	2.5	197.6	(63.7-461.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	52.9	132.4	(103.2-167.3)	Male	29	32.7	88.6	(59.3-127.2)
Female	21	20.8	100.9	(62.5-154.3)	Female	22	27.0	81.6	(51.1-123.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	9.7	144.7	(79.0-242.8)	Male	10	10.6	93.9	(45.0-172.8)
Female	5	8.5	59.0	(19.0-137.6)	Female	3	9.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	29	29.4	98.5	(66.0-141.5)
Female	189	215.3	87.8	(75.7-101.2)	Female	26	28.4	91.6	(59.8-134.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.9	nc	(nc-nc)	Male	31	24.2	128.0	(86.9-181.7)
<u>Colon / Rectum</u>					Female	10	11.8	84.7	(40.5-155.8)
Male	62	56.1	110.6	(84.8-141.7)	<u>Ovary</u>				
Female	79	60.3	131.0	(103.7-163.3)	Female	13	18.8	69.2	(36.8-118.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	13.5	200.7	(132.2-292.0)	Male	18	18.6	96.5	(57.2-152.6)
Female	5	4.0	123.9	(39.9-289.2)	Female	19	21.3	89.1	(53.6-139.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.6	nc	(nc-nc)	Male	155	164.7	94.1	(79.9-110.2)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.6	87.3	(43.5-156.3)
Male	30	28.4	105.5	(71.1-150.6)	Female	8	8.2	97.2	(41.9-191.6)
Female	21	17.4	120.6	(74.6-184.3)	<u>Testis</u>				
<u>Larynx</u>					Male	10	6.4	156.6	(75.0-288.0)
Male	11	7.8	141.3	(70.4-252.9)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	14	12.4	112.8	(61.6-189.3)
<u>Leukemia</u>					Female	33	37.4	88.1	(60.6-123.8)
Male	22	20.9	105.4	(66.0-159.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	16.4	55.0	(25.1-104.3)	Female	52	48.2	107.8	(80.5-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	18.0	94.4	(54.9-151.1)	Male	726	671.7	108.1	(100.4-116.2)
Female	6	6.6	90.4	(33.0-196.7)	Female	737	741.4	99.4	(92.4-106.9)
<u>Lung and Bronchus</u>									
Male	102	93.2	109.5	(89.3-132.9)					
Female	149	106.8	139.5	(118.0-163.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	13.3	67.9	(31.0-128.9)
Female	0	0.1	nc	(nc-nc)	Female	9	11.6	77.7	(35.5-147.5)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.9	158.7	(79.1-283.9)	Male	6	5.0	120.5	(44.0-262.3)
Female	2	2.9	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	4.5	221.3	(106.0-407.1)
Female	40	36.5	109.7	(78.4-149.4)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	8	8.5	94.0	(40.5-185.2)	<u>Ovary</u>				
Female	9	8.9	100.8	(46.0-191.3)	Female	6	3.1	194.1	(70.9-422.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	7	2.7	256.3	(102.7-528.1)
Female	0	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	32	26.7	119.8	(81.9-169.1)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	10	4.7	212.1	(101.5-390.0)	Female	1	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.4	80.8	(29.5-175.9)
Male	4	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.5	282.1	(113.0-581.2)	Female	7	8.0	87.4	(35.0-180.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	136	102.5	132.7	(111.3-156.9)
Female	0	1.0	nc	(nc-nc)	Female	128	117.8	108.6	(90.6-129.2)
<u>Lung and Bronchus</u>									
Male	18	12.9	139.8	(82.8-221.0)					
Female	20	15.4	129.7	(79.2-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	71	64.4	110.3	(86.2-139.2)	Male	64	41.9	152.7	(117.6-195.0)
Female	22	23.7	92.8	(58.1-140.4)	Female	53	32.7	162.0	(121.3-211.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.7	110.5	(60.3-185.4)	Male	11	13.6	81.0	(40.4-144.9)
Female	11	10.5	104.3	(52.0-186.7)	Female	10	11.0	90.8	(43.5-167.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.3	nc	(nc-nc)	Male	48	37.5	127.9	(94.3-169.5)
Female	303	274.6	110.3	(98.3-123.5)	Female	28	33.5	83.5	(55.5-120.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	8.8	68.2	(24.9-148.4)	Male	37	32.5	113.9	(80.2-156.9)
<u>Colon / Rectum</u>					Female	15	14.3	104.6	(58.5-172.5)
Male	72	70.3	102.5	(80.2-129.1)	<u>Ovary</u>				
Female	62	69.1	89.7	(68.8-115.0)	Female	34	23.3	145.7	(100.9-203.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	17.4	114.7	(70.0-177.1)	Male	27	23.5	114.8	(75.7-167.1)
Female	1	4.7	nc	(nc-nc)	Female	23	24.2	94.9	(60.2-142.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.9	nc	(nc-nc)	Male	237	222.6	106.5	(93.3-120.9)
Female	1	3.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	15.7	76.3	(39.4-133.2)
Male	37	38.0	97.5	(68.6-134.3)	Female	10	9.3	107.8	(51.6-198.2)
Female	21	21.5	97.6	(60.4-149.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	8.7	69.3	(25.3-151.0)
Male	12	10.2	117.4	(60.6-205.1)	<u>Thyroid</u>				
Female	1	3.1	nc	(nc-nc)	Male	23	17.1	134.5	(85.2-201.8)
<u>Leukemia</u>					Female	72	48.0	149.9	(117.3-188.8)
Male	28	26.2	107.0	(71.1-154.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	19.0	78.8	(44.1-130.0)	Female	70	62.5	112.0	(87.3-141.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	30	23.6	127.3	(85.9-181.8)	Male	987	866.8	113.9	(106.9-121.2)
Female	6	7.9	76.0	(27.8-165.5)	Female	987	904.0	109.2	(102.5-116.2)
<u>Lung and Bronchus</u>									
Male	144	117.9	122.1	(103.0-143.8)					
Female	144	127.3	113.1	(95.4-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.5	172.5	(63.0-375.4)	Male	2	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	15	12.5	119.8	(67.0-197.7)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.8	101.6	(54.1-173.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.3	nc	(nc-nc)	Male	40	48.0	83.3	(59.5-113.4)
Female	0	0.3	nc	(nc-nc)	Female	50	39.8	125.7	(93.3-165.7)
<u>Lung and Bronchus</u>									
Male	1	6.5	nc	(nc-nc)					
Female	7	5.5	128.3	(51.4-264.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.2	154.1	(49.6-359.5)	Male	6	2.3	260.2	(95.0-566.3)
Female	0	1.2	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	16.3	98.2	(56.1-159.5)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	10	2.0	501.4	(240.1-922.2)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	5	3.9	127.8	(41.2-298.3)	<u>Ovary</u>				
Female	1	3.6	nc	(nc-nc)	Female	5	1.4	361.3	(116.4-843.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	13.0	122.9	(70.2-199.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	227.1	(73.2-530.0)	Female	0	0.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	70	48.3	145.0	(113.0-183.2)
Female	0	0.5	nc	(nc-nc)	Female	49	51.3	95.5	(70.7-126.3)
<u>Lung and Bronchus</u>									
Male	2	6.1	nc	(nc-nc)					
Female	3	6.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	5.6	nc	(nc-nc)	Male	6	3.6	167.6	(61.2-364.9)
Female	5	1.7	297.5	(95.9-694.2)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	15	17.4	86.0	(48.1-141.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.0	168.8	(54.4-393.9)
<u>Colon / Rectum</u>					Female	3	1.0	nc	(nc-nc)
Male	7	6.4	109.7	(44.0-226.1)	<u>Ovary</u>				
Female	9	4.6	195.2	(89.1-370.6)	Female	4	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	12	20.3	59.2	(30.5-103.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.5	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	74	75.8	97.6	(76.6-122.5)
Female	1	0.5	nc	(nc-nc)	Female	71	59.0	120.4	(94.0-151.8)
<u>Lung and Bronchus</u>									
Male	10	10.1	98.8	(47.3-181.8)					
Female	10	9.1	109.8	(52.5-201.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	103	94.8	108.7	(88.7-131.8)	Male	53	61.4	86.3	(64.7-112.9)
Female	32	35.0	91.4	(62.5-129.0)	Female	61	50.2	121.4	(92.9-156.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	19.1	104.9	(64.0-161.9)	Male	14	19.4	72.1	(39.4-121.0)
Female	16	15.6	102.9	(58.8-167.0)	Female	14	16.0	87.5	(47.8-146.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	3.3	152.0	(49.0-354.6)	Male	46	55.2	83.4	(61.0-111.2)
Female	382	389.5	98.1	(88.5-108.4)	Female	63	49.5	127.4	(97.9-163.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	13.7	160.3	(100.4-242.7)	Male	64	44.7	143.1	(110.2-182.7)
<u>Colon / Rectum</u>					Female	25	20.8	120.3	(77.8-177.6)
Male	133	103.1	129.0	(108.0-152.9)	<u>Ovary</u>				
Female	96	103.5	92.8	(75.1-113.3)	Female	31	33.9	91.5	(62.1-129.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	28	24.1	116.2	(77.2-168.0)	Male	27	33.9	79.6	(52.5-115.9)
Female	11	6.8	161.0	(80.3-288.1)	Female	36	35.7	100.9	(70.7-139.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	8.3	107.8	(49.2-204.7)	Male	254	288.8	87.9	(77.5-99.5)
Female	8	6.7	119.6	(51.5-235.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	30	23.1	130.2	(87.8-185.8)
Male	48	52.9	90.8	(66.9-120.4)	Female	15	14.0	107.3	(60.0-177.0)
Female	29	31.0	93.5	(62.6-134.3)	<u>Testis</u>				
<u>Larynx</u>					Male	18	16.5	109.1	(64.6-172.4)
Male	17	14.1	120.6	(70.2-193.1)	<u>Thyroid</u>				
Female	5	4.4	114.4	(36.9-266.9)	Male	26	25.3	102.6	(67.0-150.3)
<u>Leukemia</u>					Female	59	77.0	76.6	(58.3-98.9)
Male	26	39.1	66.4	(43.4-97.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	28.8	86.9	(56.2-128.3)	Female	81	86.4	93.8	(74.5-116.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	62	32.6	190.0	(145.7-243.6)	Male	1323	1227.5	107.8	(102.0-113.7)
Female	16	11.4	140.0	(80.0-227.4)	Female	1362	1319.7	103.2	(97.8-108.8)
<u>Lung and Bronchus</u>									
Male	242	167.3	144.7	(127.0-164.1)					
Female	237	183.5	129.2	(113.3-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.8	95.0	(65.8-132.7)	Male	12	22.6	53.2	(27.4-92.9)
Female	7	13.2	52.9	(21.2-108.9)	Female	15	18.6	80.5	(45.0-132.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.8	88.1	(32.2-191.8)	Male	7	7.3	95.9	(38.4-197.6)
Female	5	5.9	84.0	(27.1-196.1)	Female	10	6.1	164.4	(78.7-302.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	13	20.3	63.9	(34.0-109.3)
Female	127	149.9	84.7	(70.6-100.8)	Female	18	18.8	95.6	(56.6-151.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	97.5	(31.4-227.5)	Male	7	16.6	42.3	(16.9-87.1)
<u>Colon / Rectum</u>					Female	9	7.9	113.3	(51.7-215.1)
Male	38	38.4	99.0	(70.0-135.8)	<u>Ovary</u>				
Female	44	39.0	112.7	(81.9-151.3)	Female	10	12.9	77.8	(37.2-143.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.1	66.0	(24.1-143.7)	Male	10	12.7	78.9	(37.8-145.2)
Female	3	2.6	nc	(nc-nc)	Female	7	13.5	52.0	(20.8-107.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.7	nc	(nc-nc)	Male	114	108.8	104.8	(86.4-125.9)
Female	0	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.6	93.0	(40.1-183.3)
Male	22	19.5	112.8	(70.7-170.8)	Female	6	5.3	112.3	(41.0-244.4)
Female	10	11.8	84.9	(40.7-156.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.9	nc	(nc-nc)
Male	6	5.3	113.3	(41.4-246.5)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	13	8.8	147.9	(78.7-252.9)
<u>Leukemia</u>					Female	33	28.1	117.6	(81.0-165.2)
Male	9	14.4	62.4	(28.5-118.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	10.8	nc	(nc-nc)	Female	35	33.6	104.2	(72.6-145.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	12.3	97.9	(50.5-171.0)	Male	384	456.6	84.1	(75.9-93.0)
Female	2	4.4	nc	(nc-nc)	Female	434	501.1	86.6	(78.7-95.2)
<u>Lung and Bronchus</u>									
Male	38	63.2	60.1	(42.6-82.6)					
Female	56	69.2	80.9	(61.1-105.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.8	122.8	(71.5-196.5)	Male	8	9.2	87.2	(37.6-171.9)
Female	7	5.4	129.8	(52.0-267.4)	Female	10	7.3	136.6	(65.4-251.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	5	2.9	173.0	(55.8-403.8)
Female	1	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.2	147.0	(75.9-256.8)
Female	64	59.1	108.3	(83.4-138.2)	Female	6	7.5	79.9	(29.2-173.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	7.2	69.6	(22.4-162.4)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	28	15.6	179.6	(119.3-259.6)	<u>Ovary</u>				
Female	18	15.5	116.1	(68.7-183.4)	Female	5	5.1	98.0	(31.6-228.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.7	134.7	(43.4-314.2)	Male	7	5.1	137.1	(54.9-282.5)
Female	3	1.1	nc	(nc-nc)	Female	5	5.4	92.0	(29.6-214.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	47	46.7	100.7	(73.9-133.8)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	13	8.3	157.3	(83.7-269.1)	Female	4	2.1	nc	(nc-nc)
Female	10	4.7	211.3	(101.2-388.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.8	159.1	(58.1-346.3)
<u>Leukemia</u>					Female	27	10.8	249.2	(164.2-362.6)
Male	1	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.3	nc	(nc-nc)	Female	16	13.2	120.9	(69.1-196.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.3	nc	(nc-nc)	Male	219	187.3	117.0	(102.0-133.5)
Female	3	1.8	nc	(nc-nc)	Female	245	199.7	122.7	(107.8-139.0)
<u>Lung and Bronchus</u>									
Male	29	25.2	115.2	(77.1-165.5)					
Female	32	28.6	111.7	(76.4-157.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	24.7	117.3	(78.6-168.5)	Male	12	16.3	73.6	(38.0-128.5)
Female	11	10.2	108.2	(53.9-193.6)	Female	16	13.8	115.9	(66.2-188.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	116.7	(42.6-254.0)	Male	5	5.2	95.6	(30.8-223.2)
Female	7	4.5	156.3	(62.6-322.0)	Female	3	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	16	14.6	109.2	(62.4-177.4)
Female	131	111.9	117.1	(97.9-138.9)	Female	6	14.2	42.2	(15.4-92.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.7	nc	(nc-nc)	Male	11	12.7	86.4	(43.1-154.6)
<u>Colon / Rectum</u>					Female	7	6.0	117.2	(46.9-241.4)
Male	33	27.6	119.8	(82.4-168.2)	<u>Ovary</u>				
Female	23	29.8	77.1	(48.9-115.7)	Female	13	9.6	135.0	(71.8-230.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.7	104.8	(42.0-215.9)	Male	7	9.1	77.2	(30.9-159.1)
Female	1	2.0	nc	(nc-nc)	Female	9	10.4	86.6	(39.5-164.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	62	83.9	73.9	(56.7-94.8)
Female	4	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.1	nc	(nc-nc)
Male	14	14.8	94.6	(51.7-158.7)	Female	1	4.1	nc	(nc-nc)
Female	9	8.9	101.7	(46.4-193.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.5	141.4	(45.6-330.1)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	6.9	102.0	(40.9-210.2)
<u>Leukemia</u>					Female	25	20.3	122.9	(79.5-181.4)
Male	13	10.4	125.0	(66.5-213.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.2	121.3	(58.1-223.1)	Female	27	24.9	108.6	(71.6-158.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.1	120.5	(60.1-215.7)	Male	305	334.2	91.3	(81.3-102.1)
Female	5	3.3	150.1	(48.4-350.4)	Female	391	376.8	103.8	(93.7-114.6)
<u>Lung and Bronchus</u>									
Male	36	44.7	80.5	(56.3-111.4)					
Female	43	52.5	81.9	(59.2-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	13.8	58.1	(25.0-114.6)	Male	8	8.9	89.9	(38.7-177.1)
Female	3	3.5	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.7	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	8.0	74.7	(27.3-162.6)
Female	44	47.5	92.6	(67.3-124.3)	Female	7	5.3	131.5	(52.7-270.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	0	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	11	15.3	71.9	(35.9-128.7)	<u>Ovary</u>				
Female	11	10.5	105.2	(52.4-188.2)	Female	3	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.7	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	38	46.7	81.4	(57.6-111.7)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	6	8.1	74.2	(27.1-161.5)	Female	0	1.4	nc	(nc-nc)
Female	6	3.5	170.3	(62.2-370.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.5	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.3	75.5	(30.2-155.5)
Male	5	5.6	88.6	(28.5-206.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	14	11.0	127.5	(69.7-214.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.1	nc	(nc-nc)	Male	126	184.2	68.4	(57.0-81.4)
Female	1	1.3	nc	(nc-nc)	Female	139	148.8	93.4	(78.6-110.3)
<u>Lung and Bronchus</u>									
Male	23	24.4	94.3	(59.7-141.5)					
Female	17	19.1	89.1	(51.9-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	49.7	98.6	(73.0-130.4)	Male	23	33.5	68.6	(43.5-102.9)
Female	15	19.6	76.4	(42.7-125.9)	Female	27	27.6	97.8	(64.4-142.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.8	102.0	(50.8-182.5)	Male	7	10.3	67.9	(27.2-139.9)
Female	11	8.6	127.3	(63.5-227.8)	Female	9	8.9	100.8	(46.0-191.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	30	30.0	99.9	(67.4-142.6)
Female	195	217.3	89.7	(77.6-103.2)	Female	25	27.7	90.4	(58.5-133.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.5	66.8	(21.5-155.9)	Male	20	24.8	80.8	(49.3-124.8)
<u>Colon / Rectum</u>					Female	16	11.5	138.7	(79.2-225.2)
Male	60	55.9	107.3	(81.9-138.1)	<u>Ovary</u>				
Female	42	57.2	73.4	(52.9-99.2)	Female	14	18.8	74.5	(40.7-125.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	12.9	62.1	(26.7-122.4)	Male	24	18.0	133.5	(85.5-198.6)
Female	3	3.9	nc	(nc-nc)	Female	14	19.9	70.3	(38.4-117.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	4.9	161.7	(69.6-318.5)	Male	123	155.9	78.9	(65.6-94.1)
Female	8	3.5	231.5	(99.7-456.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	12.3	170.9	(105.8-261.3)
Male	33	29.3	112.6	(77.5-158.2)	Female	12	7.8	153.2	(79.1-267.6)
Female	27	17.3	156.0	(102.8-227.0)	<u>Testis</u>				
<u>Larynx</u>					Male	8	10.1	79.5	(34.2-156.6)
Male	9	7.5	119.9	(54.7-227.6)	<u>Thyroid</u>				
Female	7	2.4	287.9	(115.4-593.3)	Male	11	14.9	73.9	(36.9-132.3)
<u>Leukemia</u>					Female	51	41.4	123.2	(91.7-162.0)
Male	27	21.3	126.7	(83.5-184.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	16.1	93.5	(52.3-154.1)	Female	36	48.3	74.5	(52.2-103.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.7	141.6	(91.6-209.0)	Male	663	663.5	99.9	(92.5-107.8)
Female	7	6.4	108.9	(43.6-224.4)	Female	729	734.4	99.3	(92.2-106.7)
<u>Lung and Bronchus</u>									
Male	117	88.3	132.5	(109.6-158.8)					
Female	136	103.1	131.9	(110.7-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	6	9.7	61.8	(22.6-134.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	10.2	87.9	(40.1-166.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	20	40.5	49.4	(30.2-76.3)
Female	0	0.3	nc	(nc-nc)	Female	19	32.9	57.8	(34.8-90.2)
<u>Lung and Bronchus</u>									
Male	2	6.0	nc	(nc-nc)					
Female	1	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	5	1.9	269.8	(87.0-629.7)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	26	22.4	116.2	(75.9-170.3)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	5	6.0	83.2	(26.8-194.3)	<u>Ovary</u>				
Female	8	5.7	140.3	(60.4-276.5)	Female	2	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	19.6	127.6	(82.6-188.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	74	75.3	98.3	(77.2-123.4)
Female	0	0.6	nc	(nc-nc)	Female	67	73.5	91.1	(70.6-115.7)
<u>Lung and Bronchus</u>									
Male	11	10.0	110.0	(54.8-196.8)					
Female	6	9.5	63.5	(23.2-138.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.8	112.6	(68.7-173.9)	Male	14	11.9	117.7	(64.3-197.5)
Female	10	7.2	139.4	(66.8-256.5)	Female	12	9.5	126.1	(65.1-220.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.8	132.4	(42.7-309.0)	Male	4	3.8	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	10.7	102.8	(51.2-183.9)
Female	82	79.6	103.1	(82.0-127.9)	Female	17	10.0	170.4	(99.2-272.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	10	9.2	108.9	(52.1-200.2)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	22	19.9	110.8	(69.4-167.7)	<u>Ovary</u>				
Female	23	20.3	113.2	(71.7-169.9)	Female	6	6.7	88.9	(32.5-193.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.8	165.3	(71.2-325.8)	Male	7	6.5	107.0	(42.9-220.4)
Female	1	1.4	nc	(nc-nc)	Female	7	7.2	97.1	(38.9-200.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	67	61.6	108.7	(84.3-138.1)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	113.2	(36.5-264.2)
Male	14	10.8	129.9	(71.0-218.0)	Female	8	2.7	291.6	(125.5-574.6)
Female	16	6.4	251.1	(143.4-407.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Leukemia</u>					Female	19	13.9	136.6	(82.2-213.3)
Male	10	7.5	133.7	(64.0-246.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.7	194.3	(96.9-347.6)	Female	22	18.0	122.1	(76.5-184.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.7	nc	(nc-nc)	Male	267	243.7	109.6	(96.8-123.5)
Female	4	2.4	nc	(nc-nc)	Female	324	265.7	121.9	(109.0-136.0)
<u>Lung and Bronchus</u>									
Male	34	32.5	104.6	(72.4-146.1)					
Female	51	38.5	132.4	(98.6-174.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.7	77.1	(35.2-146.3)	Male	8	6.9	116.5	(50.2-229.5)
Female	2	4.7	nc	(nc-nc)	Female	7	5.5	126.5	(50.7-260.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	47	46.1	102.0	(74.9-135.6)	Female	5	6.2	80.8	(26.0-188.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	5.0	99.4	(32.0-232.0)
<u>Colon / Rectum</u>					Female	6	2.6	232.4	(84.9-505.8)
Male	10	11.6	86.1	(41.2-158.4)	<u>Ovary</u>				
Female	5	13.3	37.7	(12.1-87.9)	Female	5	4.1	123.4	(39.8-287.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	40	37.2	107.6	(76.8-146.5)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.7	nc	(nc-nc)
Male	8	5.9	135.0	(58.1-266.1)	Female	1	1.8	nc	(nc-nc)
Female	6	3.8	158.9	(58.0-345.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.8	73.7	(23.8-172.0)
Male	4	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	9	10.6	85.2	(38.9-161.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.8	nc	(nc-nc)	Male	130	144.3	90.1	(75.3-107.0)
Female	1	1.5	nc	(nc-nc)	Female	141	160.0	88.1	(74.2-103.9)
<u>Lung and Bronchus</u>									
Male	16	21.0	76.2	(43.5-123.8)					
Female	14	24.2	57.7	(31.5-96.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	7.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.2	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.9	102.0	(37.2-222.0)	Male	4	4.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	5	3.4	147.6	(47.6-344.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	26	27.8	93.5	(61.1-137.0)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.4	nc	(nc-nc)
Male	9	6.7	133.5	(60.9-253.5)	<u>Ovary</u>				
Female	7	7.0	100.2	(40.1-206.4)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	5	2.3	216.3	(69.7-504.8)
Female	0	0.4	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	21	23.9	87.8	(54.3-134.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.2	153.3	(66.0-302.1)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	78	86.4	90.3	(71.4-112.7)
Female	1	0.8	nc	(nc-nc)	Female	83	90.2	92.0	(73.3-114.1)
<u>Lung and Bronchus</u>									
Male	11	11.2	98.3	(49.0-176.0)					
Female	5	11.8	42.2	(13.6-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	9	5.4	165.8	(75.7-314.8)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	5.2	192.2	(92.0-353.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	21	20.5	102.4	(63.4-156.6)
Female	0	0.1	nc	(nc-nc)	Female	19	17.1	111.1	(66.9-173.6)
<u>Lung and Bronchus</u>									
Male	1	2.8	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;